Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 14/20 | 0.67 |
| ▸ | NOS1 | P29475 | 12/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | NOS3 | P29474 | 9/20 | 0.57 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.40 |
| ▸ | CDK1 | P06493 | 2/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29798899 | 1.00 | NOS2 (0.67) | NOS2NOS1CYP2C9NOS3PDE10A | |
| SCHEMBL231090 | 1.00 | NOS2 (0.67) | NOS2NOS1CYP2C9NOS3PDE10A | |
| SCHEMBL4863062 | 0.84 | NOS2 (0.57) | NOS2NOS1CYP2C9NOS3PDE10A | |
| SCHEMBL2981397 | 0.84 | NOS2 (0.48) | NOS2NOS1CYP2C9NOS3PDE10A | |
| SCHEMBL5033970 | 0.84 | NOS2 (0.67) | NOS2NOS1CYP2C9NOS3 | |
| SCHEMBL4662911 | 0.84 | NOS2 (0.58) | NOS2NOS1CYP2C9NOS3NPC1 | |
| SCHEMBL5036979 | 0.83 | NOS2 (0.55) | NOS2NOS1CYP2C9NOS3PDE10A | |
| SCHEMBL5036437 | 0.83 | NOS2 (0.58) | NOS2NOS1CYP2C9NOS3PDE10A | |
| SCHEMBL5041184 | 0.82 | NOS2 (0.69) | NOS2NOS1CYP2C9NOS3SMN1; SMN2 | |
| SCHEMBL2835954 | 0.82 | NOS2 (0.54) | NOS2NOS1CYP2C9NOS3PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| WO-2024231899-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-11-14 | — | — | WO | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | disclosed |
| WO-2025122600-A1 | COMPOSITIONS AND METHODS FOR TREATING ABERRANT NITROSYLATION | CASE WESTERN RESERVE UNIVERSITY (US) | 2025-06-12 | — | — | WO | disclosed |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2025-01-28 | — | — | US | disclosed |
| US-12163161-B2 | In vitro method for identifying thoracic aortic aneurysms (TAA) in a subject | CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.) (ES) | 2024-12-10 | — | — | US | disclosed |
| WO-2024231899-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-11-14 | — | — | WO | disclosed |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2024-04-04 | — | — | US | disclosed |
| US-11931325-B2 | Hair-growth promoting composition and usage thereof | EADERM CO., LTD. (JP) | 2024-03-19 | — | — | US | disclosed |
| EP-3427061-B1 | USE OF SELECTIVE INOS INHIBITORS FOR TREATING THORACIC AORTIC ANEURYSM | CENTRO NAC DE INVESTIGACIONES CARDIOVASCULARES CARLOS III F S P (ES) | 2023-12-06 | — | — | EP | disclosed |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| CN-110713489-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-110183440-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-04-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | NOS2 1676/4885NOS1 3082/4885CYP2C9 1982/4885 |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | NOS2 1676/4885NOS1 3082/4885CYP2C9 1982/4885 |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | NOS2 1676/4885NOS1 3082/4885CYP2C9 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.